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Long-term treatments with dopaminergic agents are associated with adverse effects,
including augmentation. Augmentation consists of an exacerbation of restless legs
syndrome (a sleep-related movement disorder) symptoms during treatment compared to
those experienced during the period before therapy was initiated. The objective of this
study was to examine locomotor activity in rats after long-term dopaminergic treatment
and its relationship with expression of the D2 receptor, in addition to demonstrating
possible evidence of augmentation. The rats were divided into control (CTRL) and drug
(Pramipexole—PPX) groups that received daily saline vehicle and PPX treatments, respec-
tively, for 71 days. The locomotor behavior of the animals was evaluated weekly in the
Open Field test for 71 days. The expression of the dopamine D2 receptor was evaluated by
Western Blot analysis. The animals that received the PPX demonstrated a signiﬁcant
reduction in locomotor activity from day 1 to day 57 and a signiﬁcant increase in
immobility time from day 1 to day 64 relative to baseline values, but these values had
returned to baseline levels at 71 days. No changes in the expression of the D2 receptor were
demonstrated after treatment with a dopaminergic agonist. This study suggests changes in
locomotor activity in rats after long-term PPX treatment that include an immediate
reduction of locomotion and an increase in immobilization, and after 64 days, these
values returned to baseline levels without evidence of augmentation. In addition, it was
not possible to demonstrate a relationship between locomotor activity and the expression
of D2 receptors under these conditions.
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Long-term treatment with dopaminergic agents is associated
with adverse effects, including daytime sleepiness and sleep
attacks, impulse control disorder, addiction, augmentation
and other effects [1].
Augmentation occurs in up to 60% of restless legs syn-
drome (RLS) patients treated with levodopa [2] and, to a lesser
extent, dopaminergic agonists [3]. This effect was observed in
patients as an increase in severity of RLS symptoms with
increasing medication doses. Among the features of augmen-
tation are early onset of symptoms, a decrease in latency to
the onset of symptoms the during RLS inactivity, symptoms
extending to other body parts (e.g., upper limbs and trunk),
and reduced efﬁcacy of medication [4]. There are ﬁve known
factors that predispose patients to augmentation: drugs with
a low half-life, dosage increases, long-term treatments [4],
low serum ferritin levels [5], and an RLS-positive family
history [6].
Previously, studies on augmentation were not directly
based on animal models [5]. The vast majority of the research
describes augmentation as a result of the chronic treatment
of RLS. Animal models are important tools used to verify
hypotheses and decipher the details of pathophysiological
mechanisms, including the connections between genes, biol-
ogy and disease. In this context, considering the effectiveness
of PPX on the treatment of RLS and taking into account the
results of Chernoloz et al. [7] that demonstrate the facilitatory
effect of chronic PPX administration on DA neurotransmis-
sion, the assessment of the effect of long-term PPX treatment
on locomotor activity in rats has been deemed relevant.
Thus, the objective of this research was to examine
locomotor activity in rats after long-term dopaminergic
treatment and its relationship with the expression of
the D2 receptor and to demonstrate possible evidence of
augmentation.2. Materials and methods
2.1. Animals
A total of 17 three-month-old male Wistar rats (initial and
ﬁnal weight: 270 g and 380 g, respectively) at the Center
for Development of Experimental Models for Medicine and
Biology (CEDEME-UNIFESP, São Paulo, Brazil) were used in
the experiment. The rats were housed in standard polypro-
pylene cages, maintained in a temperature-controlled room
(2371 1C) with a 12:12-h light–dark cycle (lights on at 7 a.m.)
and had access to food and water ad libitum. The experi-
mental protocol was approved by the Ethics Committee of
UNIFESP (CEP: 0881/11). The animals were divided into con-
trol group (n¼8) and drug groups (n¼9).
2.2. Experimental design
Initially, the animals underwent adaptation to the Open Field
(10 min). After the adaptation period and baseline test, treat-
ment was initiated, and the animals received a daily dose ofeither the drug or saline solution at the same time each day
for 71 days. Tests were conducted in the Open Field on days 1,
8, 15, 22, 29, 36, 43, 50, 57, 64, and 71 of treatment. The
treatment occurred between 7 a.m and 8 a.m on days when
the animals did not participate in the Open Field test and
between 7 a.m and 10:30 a.m on days when they were
evaluated in the Open Field. After the last Open Field test
on day 71 of treatment, the animals were euthanized, and the
striatum was extracted.
2.3. Pharmacological treatment
The treatment consisted of a saline vehicle at 0.9% (0.1 mL/
100 g) for the control group and pramipexole (0.1 mg/kg,
dissolved in the saline solution at 0.9%) for the drug group
and was always administered at the same time of day for 71
days [8]. On days when rats were evaluated in the Open Field,
the dose was injected into the peritoneal cavity 10 min before
the beginning of the test.
2.4. Open Field
The exposure to the Open Field [9] was performed between
9 a.m. and 11 a.m., and each animal was individually placed
in the center of the apparatus and observed for 10 min.
However, only the ﬁnal 5 min was evaluated. The Open Field
consisted of a circular wooden ring measuring 81 cm in
diameter and enclosed by 41 cm-high white walls. The ceiling
was open, and the ground was divided into 19 quadrants. In
line with the circadian pattern of human RLS symptoms,
which appear or worsen during the night, all tests were
performed between 9 a.m. and 11 a.m. because rats are
nocturnal animals [10]. During the experiment, the rats were
evaluated for peripheral ambulation (number of quadrants
that the animal stepped on with four paws near the walls of
the apparatus), central ambulation (number of quadrants that
the animal stepped on with four paws that were not close to
the walls of the apparatus), total ambulation (the total
number of quadrants that the animal stepped on with four
paws) rearing (the number of times that the animal sup-
ported itself with both hind legs), total duration of grooming
(the total amount of time that the animal put its mouth or
paws on its body or head) and immobility time (the total
amount of time that the animal remained perfectly still,
moving only the vibrissae) [11].
2.5. Western Blot
After decapitation, the striatum (caudate and putamen) was
rapidly removed, and the fragments were frozen. During the
dissection, the equipment was kept at a low temperature, and
the biological material was stored at 80 1C until used. D2
dopaminergic receptor and the dopamine transporter (DAT)
expressions were evaluated by Western Blot analysis. The
tissue was homogenized in lysis buffer (1% Triton X-100, 0.5%
sodium deoxycholate, 100 mM Tris–HCl pH 8.0, 150 mM NaCl,
10 mM EDTA, 0.1% SDS, 10% glycerol, and Protease Inhibitor
Cocktail (Sigma), incubated on ice for 10 min, centrifuged at
7000g for 5 min at 4 1C, and the supernatant was collected.












































S l e e p S c i e n c e 7 ( 2 0 1 4 ) 2 0 3 – 2 0 8 205acid method (BCA, Pierce). Protein from each sample (20 mg)
was subjected to SDS-PAGE and then transferred to a PVDF
membrane. The membranes were incubated with blocking
solution for 1 h (5% skimmed milk diluted in TBS-T (50 mM
Tris pH 7.4, 150 mM NaCl, and 0.1% Tween-20), incubated
with a primary antibody diluted in TBS-T (1:500) for 1 h, and
washed 3 times with TBS-T for 5 min. After washing, mem-
branes were incubated with the diluted anti-rabbit secondary
antibody in TBS-T for 1 h (1:10,000) and washed ﬁve times
with TBS-T for 5 min. Finally, the bands of interest were
revealed with a chemiluminescent substrate (Pierce) and a
digital imaging system (MF-ChemiBIS Imaging System). After
image acquisition, quantiﬁcation of proteins of interest was
performed using the Totallab 100 (Nonlinear dynamics)
software.
2.6. Statistical analysis
The experiments were evaluated with two-way analysis of
variance (ANOVA) with repeated measures followed by post-
hoc Tukey's post-hoc test. The non-parametric Mann–Whit-
ney test was used for the D2 receptor analyses. The results
are expressed as the mean7standard error of the mean
(SEM). The level of signiﬁcance was set at po0.05.Fig. 1 – (A) Assessment in the Open Field of immobility time
in the control (saline) and drug (pramipexole) groups.
* indicates a signiﬁcant increase in the immobility time of
the drug group compared to the baseline level from days 1 to
64 (ANOVA. po0.05); @ indicates a signiﬁcant increase in the
immobility time of the control group relative to the baseline
level from days 15 to 36 of the treatment (ANOVA, po0.05);
# indicates the same day differences between the groups
between days 1 and 43 and day 57 of treatment (ANOVA,
po0.05). (B) Assessment in the Open Field of total
ambulation (number of quadrants) by the control (saline)
and drug (pramipexole) groups. * indicates a signiﬁcant
reduction in total ambulation in the drug group compared to
baseline from days 1 to 57 (ANOVA, po0.05); # indicates
same day differences between the groups on days 8 and 43
of treatment (ANOVA, po0.05). H s: hundred seconds.3. Results
3.1. Immobility time
ANOVA for the repeated measures revealed signiﬁcant effects
for the factors groups (F(1.15)¼24.027, po0.001) and time
(F(11.165)¼ 14.326, po0.001) and the interaction of group-
s time (F(11.165)¼ 4.841, po0.001). Fig. 1A shows that the
drug group exhibited a signiﬁcant increase in the immobility
time compared to baseline from day 1 to 64 of the treatment.
It also shows a signiﬁcant increase in the immobility time for
the drug group compared to baseline from days 15 to 36 of the
treatment. Moreover, the drug group exhibited a signiﬁcant
increase relative to the control group between days 1 and 43
and on day 57 of the treatment. The control group exhibited a
signiﬁcant increase in immobility time relative to baseline
from days 15 to 36 of the treatment.
3.2. Total ambulation
ANOVA for repeated measures revealed signiﬁcant effects for
the factor time (F(11.165)¼2.7735, po0.001), and the interaction
groups time (F(11.165)¼3.9991, po0.001). Fig. 1B shows that
the drug group exhibited a signiﬁcant reduction in total
ambulation relative to baseline from days 1 to 57 of the
treatment. In addition, the control group exhibited a signiﬁ-
cant increase in total ambulation compared to the drug group
on days 8 and 43 of treatment.
3.3. Rearing
ANOVA for repeated measures revealed a signiﬁcant effect for
the factor time (F(11.165)¼ 3.8419, po0.001). Fig. 2A shows thatthe drug group demonstrated a signiﬁcant decrease in rearing
relative to baseline from days 1 to 43 of the treatment. This
ﬁgure also shows that the control group exhibited a signiﬁ-
cant decrease in rearing in relative to baseline from days 15 to
29 of the saline solution treatment. The control group
exhibited a signiﬁcant increase compared to the drug group
on day 1 of the treatment.
3.4. Grooming (time)
ANOVA for repeated measures revealed signiﬁcant effects for
the factors groups (F(1.15)¼ 6.441, po0.02273) and time
(F(11.165)¼ 6.767, po0.001). Fig. 2B shows that the drug group
demonstrated a signiﬁcant decrease in grooming relative to
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Fig. 2 – (A) Assessment of rearing of Wistar rats in the
control (saline) and drug (pramipexole) groups in the Open
Field. * indicates a signiﬁcant decrease in rearing in the drug
group compared to the baseline level from days 1 to 43 of
treatment (ANOVA, po0.05); @ indicates a signiﬁcant
decrease in rearing in the control group relative to baseline
from days 15 to 29 of the treatment (ANOVA, po0.05);
# indicates a same day difference between the groups on
day 1 of treatment (ANOVA, po0.05). B assessment of
grooming (time, seconds) in the Open Field in the control
(saline) and drug (pramipexole) groups. * indicates a
signiﬁcant decrease in grooming in the drug group
compared to baseline from days 1 to 71 of treatment
(ANOVA, po0.05); @ indicates a signiﬁcant decrease in
grooming in the control group relative to baseline from days
1 to 8 and days 22 to 71 of treatment (ANOVA, po0.05); #
indicates a same day difference between the groups on day
15 of treatment (ANOVA, po0.05).
Fig. 3 – Analysis of the relative expression of the D2
dopamine receptor in the control and drug (Pramipexole)
groups (Mann–Whitney, p40.05).
S l e e p S c i e n c e 7 ( 2 0 1 4 ) 2 0 3 – 2 0 8206that the control group showed a signiﬁcant decrease in
grooming relative to baseline from days 1–8 to days 22–71
of the treatment. There were also signiﬁcant differences
between the groups on day 15 of the treatment.3.5. D2 receptor expression
The results showed no signiﬁcant differences in the expres-
sion of the dopamine D2 receptor between the control and
drug groups after 71 days of treatment (Fig. 3).4. Discussion
This study aimed to assess the long-term effects of dopami-
nergic treatment (PPX) on locomotor activity and their rela-
tionship with the expression of the D2 receptor.
Pramipexole (PPX) is a non-ergot agonist of D2/D3 that is
used for the treatment of RLS and Parkinson's disease [12].
The increased effectiveness of this medication has been
demonstrated by numerous multicenter studies [13]. How-
ever, many patients have experienced residual symptoms
during treatment, and from 12% to 25% of patients discon-
tinue use due to either side effects or the loss of efﬁcacy [1].
Ferini-Strambi [14] estimated that 8.3% of 60 patients treated
for 6 months with dopamine agonists showed augmentation.
In another study with a mean duration of 27.2 months, Silber
et al. [15] found that 33% of the 49 patients developed
augmentation after 13.8 months of treatment. García-
Borreguero et al. [16] suggested that 20% of patients develop
augmentation after 1 year of treatment, and the rate
increases to 30% after 2 years.
Currently, the precise nature of augmentation is not fully
understood. What is known is that it is caused by a dis-
turbance of the dopaminergic system [5]. It is believed that
the increased dopaminergic state is caused by excessive
stimulation of D1 compared with D2 receptors, which leads
to decreased sensitivity and a down-regulation of the D1
receptor. It is also believed that this hyper-dopaminergic
state leads to a supersensitivity of the dopamine receptor,
similar to a mechanism proposed for tardive dyskinesia.
Another theoretical possibility based on excessive orexinergic
stimulation states that this stimulation would lead to a
hyper-motor syndrome via the large projections of orexiner-
gic neurons to the monoaminergic system and the anterior
horn cells of the spinal cord [4].
The results of this study showed that animals treated with
PPX for 71 days initially exhibited reduced locomotor activity
and increased immobilization, and after 64 days, these
behavioral characteristics started to return to baseline levels.
Using PET, Cervenka et al. [17] demonstrated increased
availability of D2 receptors in patients with RLS. This
interpretation is consistent with the dopaminergic neuro-
transmission hypothesis in RLS, wherein the increased
S l e e p S c i e n c e 7 ( 2 0 1 4 ) 2 0 3 – 2 0 8 207concentration of receptors may be due to the positive regula-
tion of the receptor in response to low concentrations of
dopamine. Interestingly, sustained treatment with PPX
(which over stimulates somatodendritic D2/D3 receptors)
can lead to a decrease in D2/D3 receptor responsiveness
and a subsequent restoration of the mean ﬁring rate of DA
neurons [7]. The present study showed no signiﬁcant differ-
ence in D2-like receptor expression due to long-term PPX
administration (71 days). However, it is known that contin-
uous stimulation during treatment down-regulates the num-
ber of receptors, and, by analyzing Fig. 3, there seems to be a
tendency for a reduction of D2 receptor expression. This
ﬁnding is consistent with results previously reported by
Chernoloz et al. [7] that demonstrated a decreased sensitivity
and density of D2-like receptors following chronic adminis-
tration of the D2-like agonist PPX
Studies have shown that the development of regular
locomotion, requires a synergistic interaction between the
dopaminergics D1 and D2 [18] or D1 and D3 receptors [19,20].
However, activation of the postsynaptic D2 receptors can
increase locomotion. In the hyper-dopaminergic phase of RLS
treatment, hyper-excitability of the dopaminergic system
leads to a reduction of the ﬂexor reﬂexes and an initial
increase of the delayed ﬂexor reﬂexes [5]. This result was
also conﬁrmed in the present study because during the initial
phase of the PPX treatment, the rats showed a signiﬁcant
reduction in locomotion and a substantial increase in
immobilization.
The present study has some limitations. Despite relatively
long-term treatment, our animals did not demonstrate evi-
dence of augmentation (by the Open Field test). This may be
due to possible tolerance acquired during the long treatment
period. Thus, an increase in the drug dose might have
demonstrated the augmentation that usually occurs in
humans.
In summary, the present results demonstrate the effects
of long-term dopaminergic treatment on locomotor behavior
in rats. Rats that received PPX treatment for 71 days showed
an immediate reduction in locomotion and an increase in
immobilization, and after 64 days, these values returned to
baseline levels without evidence of augmentation. In addi-
tion, under these conditions it was not possible to demon-
strate the relationship between locomotor activity and the
expression of D2 receptors.
Thus, for future studies, it is important consider experi-
ments using spontaneously hypertensive rats, an animal
model of RLS previously reported by Esteves et al., [21], to
investigate the underlying pathophysiology of augmentation.Conﬂict of interest
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